Skip to content

Eptacog alfa (activated)

NovoSeven (eptacog alfa (activated)) is a protein pharmaceutical. Eptacog alfa (activated) was first approved as NovoSeven on 1996-02-23. It has been approved in Europe to treat factor VII deficiency, hemophilia a, hemophilia b, and thrombasthenia.
Trade Name NovoSeven
Common Name Eptacog alfa (activated)
Indication factor vii deficiency, hemophilia a, hemophilia b, thrombasthenia
Drug Class
Eptacog alfa (activated)
Get full access now